Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Citadel-123: A Phase I Clinical Trial to Assess the Activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I Inhibitor (123I-ATT001) Directly Administered in Subjects With Relapsed Glioblastoma.

NCT06650605 is registered in ClinicalTrials.gov with Theragnostics Ltd as lead sponsor.

NCT NCT06650605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06650605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Citadel-123: A Phase I Clinical Trial to Assess the Activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I Inhibitor (123I-ATT001) Directly Administered in Subjects With Relapsed Glioblastoma.
Lead sponsor
Theragnostics Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 4, 2024
Completion date
March 1, 2026
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioma glioblastoma multiforme